Patt
Debra Patt, MD, PhD, MBA, is a medical oncologist/hematologist and breast cancer specialist who practices in Austin, Texas, for Texas Oncology. She is the current president of the Community Oncology Alliance, a member of the board of directors for the American Society of Clinical Oncology, and medical director for public policy for The US Oncology Network. As part of a wide-ranging interview, Evidence-Based Oncology (EBO) asked Patt about the US surgeon general’s January 3, 2025, advisory on alcohol and cancer risk.
EBO: What were your thoughts on the surgeon general’s advisory?
Patt: I saw the surgeon general’s report on alcohol and cancer, and that increased alcohol intake is associated with some particular cancers, specifically, head and neck cancer, esophageal cancer, breast cancer, liver cancer, and colorectal cancer.
Alcohol intake is associated with an increased risk of those cancers; in particular, heavy alcohol intake is associated with an increased risk of those cancers. This is important information to get out. We need to be talking to our patients about it and allow them to make educated decisions about how they might modify their lifestyle in order to continue to live cancer free.
Real-World Data Show Bevacizumab Benefits Only High-Risk Patients With Epithelial Ovarian Cancer
May 13th 2025In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with epithelial ovarian cancer and high-risk prognostic factors.
Read More
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Finding the Right Biomarker Is Key to the TIGIT Puzzle, Experts Say
May 12th 2025Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, align with recent bad news for this once-promising therapeutic target. But investigators involved in TIGIT studies say the problem is finding the right biomarker.
Read More